Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
Jie ZhangTong-Zhang XianYu TengXiuzhi WangMing-Xiao WuChen LiWeihao WangFuli ManXianbo ZhangXiaoxia WangLi-Xin GuoPublished in: International journal of clinical practice (2022)
BMI scores improved after exenatide treatment for 52 weeks in T2DM patients. Weight loss was affected by baseline body weight and blood glucose level. In addition, BMI reduction from the baseline to 52 weeks was positively correlated with baseline HbA1c, hsCRP, and SBP. Trial Registration. Chinese Clinical Trial Registry (ChiCTR-1800015658).
Keyphrases
- body mass index
- blood glucose
- clinical trial
- body weight
- weight loss
- end stage renal disease
- weight gain
- glycemic control
- phase ii
- study protocol
- ejection fraction
- newly diagnosed
- phase iii
- peritoneal dialysis
- open label
- prognostic factors
- metabolic syndrome
- blood pressure
- roux en y gastric bypass
- gestational age
- patient reported outcomes
- gastric bypass
- insulin resistance
- replacement therapy